LabGenius: Using synthetic biology, machine learning and robotics to discover a safer, more effective Nectin-4 T-cell engager for advanced cancers.

LabGenius是一家英国生物技术公司，它结合了机器人自动化、合成生物学和先进的机器学习，以探索蛋白质健康的前景，同时改善多种药物的性能。LabGenius的使命是通过率先开发智能机器人平台(**EVA(Tm)**)来加速发现下一代治疗性抗体，该平台能够设计、进行并关键地从自己的实验中学习。癌症是全球头号死因，超过40%的男性和女性在有生之年被诊断为癌症(John Hopkins，2022)。2021年，癌症的经济成本估计为9300亿GB，而且这一成本预计还会上升。仅在英国，每年就有35万新的癌症病例(英国国家统计局，2022)。常见癌症包括肺部(13%)、膀胱癌(3%)和卵巢癌(2%)(Siegel，2022)。T细胞激活器(TCE)被认为是一种在不对身体其他部位产生负面影响的情况下成功治疗癌症的方法，然而，到目前为止，只有两个TCE上市，因为许多人由于严重的副作用和低效率而在临床试验中失败。在这个项目中，LabGenius将使用他们的机器学习驱动的方法来优化用于治疗晚期癌症的T细胞激活器，使具有更好疗效和安全性的候选人能够被带入未来的开发。LabGenius的技术平台使其有别于在发现候选药物的速度和质量方面的竞争。

LabGenius is a UK biotechnology company that combines robotic automation, synthetic biology and advanced machine learning to explore protein fitness landscapes and improve multiple drug properties simultaneously. LabGenius' mission is to accelerate the discovery of next-generation therapeutic antibodies by pioneering the development of a smart robotic platform (**EVA(tm)**) that is capable of designing, conducting and, critically, learning from its own experiments.Cancer is the number one cause of death worldwide with over 40% of men and women being diagnosed with cancer in their lifetime (John Hopkins, 2022). The economic cost of cancer was estimated at £930 billion in 2021 and this cost is expected to rise. In the UK alone there are \>350,000 new cases of cancer a year (ONS,2022). Common cancers include those affecting the lungs (13%), bladder (3%) and ovaries (2%) (Siegel,2022). T-cell engagers (TCE) are seen as a way forward to treat cancers successfully without negatively impacting the rest of the body, however, to date only two TCEs have been marketed as many fail in clinical trials due to severe adverse side effects and low efficacy.In this project, LabGenius will use their machine learning-driven approach to optimise a T-cell engager for the treatment of advanced cancers, enabling candidates with better efficacy and safety to be taken forward for future development. LabGenius' technology platform sets it apart from the competition in speed and quality of drug candidates discovered.